Christy Dawn Calvin, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 207 E 7th St, Hays, KS 67601 Phone: 888-878-6881 Fax: 785-625-5759 |
Amanda Pfannenstiel, RN Registered Nurse - General Practice Medicare: Not Enrolled in Medicare Practice Location: 94 Lewis Dr, Hays, KS 67601 Phone: 785-625-3257 Fax: 785-625-8557 |
Shelby Mattke, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1923 E 22nd St, Hays, KS 67601 Phone: 785-656-1233 Fax: 785-628-8719 |
Janell Nease, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2216 Felten Dr, Hays, KS 67601 Phone: 816-745-7194 |
Alexis Marie Ibarra, DNP, APRN-C Registered Nurse Medicare: Medicare Enrolled Practice Location: 2400 Main Street Ter, Hays, KS 67601 Phone: 785-656-0536 |
News Archive
Since the 1970s, studies have suggested that infants can imitate facial gestures, finger movements, and other actions just hours after birth. University of Miami Assistant Professor Elizabeth Simpson studies this phenomenon, known as neonatal imitation, in babies from birth to one year of life in her Social Cognition Lab in the Department of Psychology's Child Division.
Literally hundreds of clinical trials, including some that have gained widespread attention, have been done on the possible benefits of omega-3 fatty acids for the prevention of heart disease - producing conflicting results, varied claims, and frustrated consumers unsure what to believe.
Delcath Systems, Inc. (Nasdaq: DCTH), a Manhattan headquartered medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it has signed a three-year lease with the option to buy on a 10,000 square foot facility in Queensbury, New York in which it plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System.
The American Dietetic Association has published an updated position paper that addresses the nutrition aspects of health care for people with developmental disabilities and special health care needs.
Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
› Verified 4 days ago